A Phase 4 interventional study of Roflumilast and Placebo in COPD, COPD Exacerbation and Lung Diseases, sponsored by AstraZeneca. Completed at 338 sites in 17 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-13.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one has the largest enrollment, is one of 5 that started in 2011, is one of 8 in phase 4, and was the 15th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,354 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 6th largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 19 in phase 4, and was the 108th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast
Drug: Roflumilast
Placebo
Drug: Placebo
Roflumilast 500 µg, oral administration, once per day
Also known as: Daliresp
Dose-matched placebo, oral administration, once per day.
Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year.
Rate of moderate or severe COPD exacerbations, defined as requiring oral or parenteral glucocorticosteroids (moderate) or requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.
Time frame: Baseline to Week 52
Rate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations)
Rate of moderate or severe COPD exacerbations, defined as requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.
Time frame: Week 0 (Visit 2) to Week 52
Rate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics
Rate of moderate or severe COPD exacerbations treated with antibiotics during the double-blind treatment period.
Time frame: Week 0 (Visit 2) to Week 52
Mean Change in Predose Forced Expiratory Volume in 1 Second (FEV1)
Mean change from randomization (Visit 2) over 52 weeks of treatment in predose forced expiratory volume in 1 second (FEV1)
Time frame: Week 0 (Visit 2) to Week 52
Recruitment occurred from September 2011 to October 2014 for a total of 380 study centers screened patients for the study: Italy, Spain, United States, Ukraine, Argentina, Russia, Philippines, Romania, Serbia, Canada, Malaysia, Thailand, Mexico, Peru and Taiwan.
| Milestone | Placebo | Roflumilast |
|---|---|---|
| Started | 1176 | 1178 |
| Completed | 922 | 841 |
| Not completed | 254 | 337 |
| Withdrew: Protocol violation | 43 | 45 |
| Withdrew: Other reasons, such as copd exacerbation | 44 | 44 |
| Withdrew: Deterioration in pulmonary function | 1 | 4 |
| Withdrew: Lack of efficacy | 10 | 5 |
| Withdrew: Adverse event | 64 | 138 |
| Withdrew: Withdrawal by subject | 63 | 67 |
| Withdrew: Military conflict - site terminated | 20 | 21 |
| Withdrew: Lost to follow-up | 9 | 13 |
Rate of moderate or severe COPD exacerbations, defined as requiring oral or parenteral glucocorticosteroids (moderate) or requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.
| COPD exacerbations per patient per year | Placebo | Roflumilast |
|---|---|---|
| Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year. | 1.27 (1.17 to 1.39) | 1.17 (1.06 to 1.28) |
Rate of moderate or severe COPD exacerbations, defined as requiring hospitalization and/or leading to death (severe), during the double-blind treatment period.
| COPD exacerbations per patient per year | Placebo | Roflumilast |
|---|---|---|
| Rate of COPD Exacerbations That Led to Hospitalization or Death (ie, Severe COPD Exacerbations) | 0.29 (0.25 to 0.34) | 0.28 (0.23 to 0.33) |
Rate of moderate or severe COPD exacerbations treated with antibiotics during the double-blind treatment period.
| COPD Exacerbations per Patient per Year | Placebo | Roflumilast |
|---|---|---|
| Rate of Moderate or Severe COPD Exacerbations or COPD Exacerbations Treated With Antibiotics | 1.45 (1.34 to 1.57) | 1.31 (1.20 to 1.43) |
Mean change from randomization (Visit 2) over 52 weeks of treatment in predose forced expiratory volume in 1 second (FEV1)
| Liters | Placebo | Roflumilast |
|---|---|---|
| Mean Change in Predose Forced Expiratory Volume in 1 Second (FEV1) | -0.0091 ± 0.0047 | 0.0441 ± 0.0048 |
Collected over Adverse event data was collected from the start of the 52-week double-blind treatment period, to 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 162/1,174 (13.8%) | 188/1,174 (16%) |
| Roflumilast | — | 180/1,178 (15.3%) | 317/1,178 (26.9%) |
| Event | Placebo | Roflumilast |
|---|---|---|
| PneumoniaInfections and infestations | 45/1174 | 47/1178 |
| Lobar pneumoniaInfections and infestations | 7/1174 | 1/1178 |
| Acute myocardial infarctionCardiac disorders | 1/1174 | 7/1178 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 6/1174 | 7/1178 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/1174 | 7/1178 |
| Non-cardiac chest painGeneral disorders | 3/1174 | 6/1178 |
| Atrial fibrillationCardiac disorders | 5/1174 | 4/1178 |
| Cardiac arrestCardiac disorders | 0/1174 | 5/1178 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/1174 | 5/1178 |
| FallInjury, poisoning and procedural complications | 4/1174 | 3/1178 |
| Event | Placebo | Roflumilast |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 36/1174 | 119/1178 |
| Weight decreasedInvestigations | 27/1174 | 91/1178 |
| HeadacheNervous system disorders | 48/1174 | 80/1178 |
| Upper respiratory tract infectionInfections and infestations | 66/1174 | 60/1178 |
| NauseaGastrointestinal disorders | 30/1174 | 62/1178 |
The demographic information provided here is for the safety population. The safety population (numbering 2352 patients) of the trial does not include 2 patients from the enrolled population (numbering 2354 patients), due to a protocol deviation for one patient and an adverse event for a second patient, both in the placebo arm
| Age, Continuous(years) | Placebo | Roflumilast | Total |
|---|---|---|---|
| Mean | 64.5 ± 8.4 | 64.4 ± 8.8 | 64.5 ± 8.6 |
| Age, Customized(Participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| Adults 40-65 years | 634 | 640 | 1274 |
| Adults over 65 years | 540 | 538 | 1078 |
| Sex/Gender, Customized(Participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| Male | 794 | 821 | 1615 |
| Female | 380 | 357 | 737 |
| Race/Ethnicity, Customized(Participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| White | 944 | 935 | 1879 |
| Black or African American | 27 | 35 | 62 |
| Asian | 170 | 167 | 337 |
| American Indian or Alaska Native | 6 | 16 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Other | 27 | 23 | 50 |
| Region of Enrollment(participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| Colombia | 7 | 10 | 17 |
| Argentina | 197 | 198 | 395 |
| Russian Federation | 77 | 77 | 154 |
| Romania | 55 | 54 | 109 |
| United States | 458 | 457 | 915 |
| Philippines | 130 | 131 | 261 |
| Ukraine | 95 | 95 | 190 |
| Malaysia | 6 | 7 | 13 |
| Thailand | 18 | 16 | 34 |
| Spain | 6 | 6 | 12 |
| Canada | 14 | 15 | 29 |
| Taiwan | 7 | 6 | 13 |
| Italy | 0 | 1 | 1 |
| Mexico | 22 | 22 | 44 |
| Serbia | 47 | 47 | 94 |
| Peru | 35 | 36 | 71 |
| Ethnicity(Participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| Hispanic or Latino | 272 | 268 | 540 |
| Not Hispanic or Latino | 902 | 910 | 1812 |
| ICS/LABA Therapy(Participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| Advair | 766 | 768 | 1534 |
| Symbicort | 408 | 410 | 818 |
| Long-acting muscarinic antagonist(s) (LAMA) use(Participants) | Placebo | Roflumilast | Total |
|---|---|---|---|
| LAMA | 546 | 548 | 1094 |
| No-LAMA | 628 | 630 | 1258 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 338 sites across 17 countries. Choose a country and city above to see the rest.
Ran from Sep 2011 to primary completion in Nov 2015, 50 months.
Results were first posted in Jan 2017, 1 year 1 month after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 50 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →